VAXNEUVANCE

Product Overview

About VAXNEUVANCE

VAXNEUVANCE is a pneumococcal conjugate vaccine that helps protect against invasive pneumococcal disease caused by certain serotypes of Streptococcus pneumoniae. This vaccine is designed to help prevent serious and potentially life-threatening infections, such as meningitis and sepsis, particularly in individuals who are at increased risk due to age or underlying health conditions.

Key Benefits & Uses

• Prevention of invasive pneumococcal disease, including meningitis and sepsis
• Protection against certain serotypes of Streptococcus pneumoniae, including serotypes 22F, 19A, 14, 1, 6A, 33F, 9V, 18C, 4, 23F, 6B, 5, 3, 19F, and 7F
• Recommended for use in individuals who are at increased risk of pneumococcal disease, such as older adults and those with certain underlying health conditions

Active Ingredient & Action

VAXNEUVANCE contains pneumococcal polysaccharide serotypes conjugated to Corynebacterium diphtheriae CRM-197 protein, which helps to stimulate an immune response and provide protection against pneumococcal disease. The active ingredients, including PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, and others, work together to help prevent invasive pneumococcal disease by inducing immunity against the specific serotypes included in the vaccine.

Important Notes

As with any vaccine, VAXNEUVANCE may not provide 100% protection against pneumococcal disease, and it is not a treatment for existing infections. It is essential to follow the recommended vaccination schedule and to consult with a healthcare professional to determine the best course of vaccination for individual needs and circumstances. Additionally, individuals should report any side effects or concerns to their healthcare provider, as with any medical treatment.